Roles of the physical environment in health-related quality of life in patients with chronic obstructive pulmonary disease.


Journal

Environmental research
ISSN: 1096-0953
Titre abrégé: Environ Res
Pays: Netherlands
ID NLM: 0147621

Informations de publication

Date de publication:
01 2022
Historique:
received: 14 04 2021
revised: 28 07 2021
accepted: 31 07 2021
pubmed: 12 8 2021
medline: 15 12 2021
entrez: 11 8 2021
Statut: ppublish

Résumé

Many clinical and psychological factors are known to influence the health-related quality of life (HRQL) in chronic obstructive pulmonary disease (COPD). However, research on whether environmental factors, such as air pollution, noise, temperature, and blue/green spaces also influence HRQL in COPD has not been systematically investigated. To assess the relationship between air pollution, road traffic noise, temperature, and distance to blue/green spaces and respiratory-specific HRQL in COPD. We used cross-sectional data from a multicenter study in 407 stable mild-to-very severe COPD patients from Barcelona (Catalonia). Patients answered the COPD Assessment Test (CAT) and Clinical COPD Questionnaire (CCQ). Individual residential exposure to air pollutants (nitrogen dioxide [NO Of those patients, 85 % were male and had a mean (SD) age of 69 (9) years, CAT score of 12 (7), CCQ-total score of 1.4 (1.0), and post-bronchodilator forced expiratory volume in 1 s (FEV Our study showed that increased air pollution, particularly NO

Identifiants

pubmed: 34380048
pii: S0013-9351(21)01122-1
doi: 10.1016/j.envres.2021.111828
pii:
doi:

Substances chimiques

Air Pollutants 0
Particulate Matter 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

111828

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Subhabrata Moitra (S)

ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

Maria Foraster (M)

ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain; PHAGEX Research Group, Blanquerna School of Health Science, Universitat Ramon Llull (URL), Barcelona, Spain.

Ane Arbillaga-Etxarri (A)

ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain; AFDSalud/HealthPass Group, Physiotherapy, Faculty of Psychology and Education, University of Deusto, Donostia-San Sebastián, Spain.

Alicia Marín (A)

Pneumology Department, Hospital Germans Trias i Pujol, Badalona, Spain.

Anael Barberan-Garcia (A)

Respiratory Clinic Institute, Hospital Clinic of Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.

Diego A Rodríguez-Chiaradia (DA)

Universitat Pompeu Fabra (UPF), Barcelona, Spain; Pneumology Department, Institut Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain; CIBER Respiratory Disease (CIBERES), Barcelona, Spain.

Eva Balcells (E)

Universitat Pompeu Fabra (UPF), Barcelona, Spain; Pneumology Department, Institut Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain; CIBER Respiratory Disease (CIBERES), Barcelona, Spain.

Maria Koreny (M)

ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

Pere Torán-Monserrat (P)

Unitat de Suport a la Recerca Metropolitana Nord, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Mataró, Spain.

Pere Vall-Casas (P)

Universitat Internacional de Catalunya (UIC), Barcelona, Spain.

Robert Rodríguez-Roisin (R)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; CIBER Respiratory Disease (CIBERES), Barcelona, Spain.

Judith Garcia-Aymerich (J)

ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. Electronic address: Judith.garcia@isglobal.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH